Participants 105 173 5
patients with unresectable and/or recurrent advanced gastric cancer.
Participants 459 833 5
Patients with unresectable and/or recurrent advanced gastric cancer were randomly assigned to receive one of the two regimens: S-1 (40 mg m(-2) twice daily) on days 1-14 plus paclitaxel (60 mg m(-2)) on days 1, 8, and 15 of a 4-week cycle (S-1+paclitaxel) or S-1 (40 mg m(-2) twice daily) on days 1-21 plus cisplatin (60 mg m(-2)) on day 8 of a 5-week cycle (S-1+cisplatin).
Participants 990 1059 4
A total of 83 patients were eligible for safety and efficacy analyses
Participants 1651 1689 3
patients with advanced gastric cancer.
